Pharmacological Neuroplastic Recalibration of the Respiratory Chemoreflex

A Three-Drug Protocol for Durable Adaptation of Respiratory Controller Gain in High-Loop-Gain Sleep-Disordered Breathing

Locke | May 2026

This document is a theoretical framework intended for expert evaluation by researchers and clinicians working in sleep medicine and respiratory physiology. It is not a clinical protocol and should not be implemented without formal research oversight. Published evidence supports many of the component links independently; the integrated three-drug mechanism remains untested.

Abstract

Current pharmacological treatment of high-loop-gain sleep apnea combines acetazolamide with a dual orexin receptor antagonist (DORA) to stabilize respiratory control during sleep. This combination is effective as ongoing treatment, but only approximately 20% of patients can later be weaned off acetazolamide, suggesting that stabilization alone may not produce durable adaptation. This document proposes that the DORA, while effective for acute sleep stabilization, may inadvertently limit the consolidation process necessary for durable weaning. Published evidence demonstrates that orexin signaling is a documented requirement for ventilatory long-term facilitation (vLTF), the principal mechanism of respiratory neuroplasticity. By blocking orexin receptors nightly, the DORA may prevent the activity-dependent consolidation necessary for the respiratory control system to learn a durable new baseline.

A revised three-drug architecture is proposed: (1) low-dose acetazolamide to shift the pH baseline and drive galanin-mediated chemoreceptor adaptation; (2) zuranolone, an oral neurosteroid GABA-A modulator, to provide arousal management via direct extrasynaptic GABA-A buffering without blocking orexin; and (3) intermittent yohimbine as a controlled noradrenergic and orexinergic stress challenge that forces the carotid body and retrotrapezoid nucleus to practice handling stress at the new pH set point. This architecture is modeled on the physiology of high-intensity breath-hold training, which produces the most durable chemoreflex recalibration documented outside of pharmacology and which triggers, rather than suppresses, acute orexin release.

The framework reconciles multiple clinical observations from specialized sleep medicine practice, including the 20/80 weaning split, the sex difference in weaning success, the exclusion of heart failure and atrial fibrillation patients, the long-term requirement for sedatives, and the role of EERS in the weaning process.

The Problem: Stabilization Without Teaching

Current pharmacological treatment of high-loop-gain sleep apnea is effective as ongoing treatment but rarely produces durable adaptation that persists after drug withdrawal. The leading clinical protocol combines acetazolamide with a DORA. This combination is effective while both drugs are present.

Clinical observations from a specialized sleep medicine center reveal the limitation. Approximately 20% of high-loop-gain patients can be weaned off acetazolamide after roughly six months while using Enhanced Expiratory Rebreathing Space (EERS). The other the remaining roughly 80% cannot be weaned. Men are harder to wean than women. Patients with heart failure or atrial fibrillation essentially cannot be weaned. Sedatives appear to be needed long-term even when acetazolamide is successfully discontinued.

The fact that only about 20% of patients can wean suggests that something in the current protocol may be limiting the nervous system from learning a new baseline. The drugs stabilize the system every night, but stabilization and adaptation are not the same thing. Pharmacological stabilization protects the system from acute instability but may not provide the activity-dependent stimulus required for structural adaptation.

The Breath-Hold Model: What Durable Adaptation May Look Like

Among non-pharmacological interventions, high-intensity breath-hold training may produce some of the most durable chemoreflex adaptations observed. Elite freedivers and advanced respiratory training practitioners demonstrate markedly blunted ventilatory responses to hypercapnia and hypoxia, suggesting that repeated, controlled exposure to extreme CO₂/pH stress can durably reduce chemoreflex controller gain.

During the struggle phase of a maximal breath hold, end-tidal CO₂ spikes to approximately 65 mmHg, SpO₂ can plummet to approximately 73%, and the autonomic nervous system enters severe conflict. This is associated with significant release of catecholamines, orexin, BDNF, and cortisol. Measurements in Korean Haenyeo diving populations indicate that acute breath-hold and cold-water immersion stress elevate systemic orexin-A levels.

If orexin release during acute respiratory stress were purely pathological, breath-hold training would further sensitize the chemoreflex and worsen respiratory instability. Trained practitioners show durably reduced chemoreflex gain. One possibility is that the orexin and catecholamine spike during the struggle phase serves as a neuroplastic consolidation signal. Because the stressor is voluntarily initiated and terminated, the system may interpret it as an environmental demand requiring structural adaptation rather than as a threat requiring sensitization.

The Durability Question: Why Stabilization May Not Produce Adaptation

DORAs are effective for ongoing treatment: they improve sleep quality, reduce arousal fragmentation, and are well-tolerated. The question raised here is different. If the goal shifts from ongoing treatment to time-limited adaptation, to producing durable changes that persist after the drugs are withdrawn, does continuous orexin blockade during the adaptation window come at a cost to the consolidation process that would make withdrawal possible?

Orexin Is Required for Respiratory Neuroplasticity

Ventilatory long-term facilitation (vLTF), a persistent increase in respiratory motor output following intermittent hypoxia, is the primary documented form of respiratory neuroplasticity. Published evidence demonstrates that vLTF is dependent on an intact orexin system. In orexin neuron-ablated mice, phrenic long-term facilitation is severely attenuated. Orexin activates OX1R, a Gq-protein coupled receptor that triggers intracellular calcium release and PKC cascades, leading to AMPA receptor trafficking and synaptic strengthening. Without this permissive excitatory drive, the serotonergic-BDNF cascade triggered by intermittent stress fails to exceed the threshold for permanent synaptic scaling.

A clarification on directionality: vLTF demonstrates that orexin is required for respiratory neuroplasticity, but it does not follow that orexin exclusively drives gain upward. Like BDNF, which is required for both long-term potentiation and long-term depression depending on the activity pattern, orexin may serve as a permissive consolidation signal whose direction is determined by the physiological context. When acetazolamide has shifted the pH baseline and galanin is already upregulated in the RTN, a phasic orexin spike may consolidate this galanin-dominant, lower-gain state rather than driving facilitation. The orexin determines durability; the shifted environment determines direction.

DORAs Block Both Tonic and Phasic Orexin

The orexin system operates in two distinct modes, analogous to the tonic/phasic framework established for the locus coeruleus-norepinephrine system (Aston-Jones and Cohen, 2005) and for dopamine (Grace, 1991; Schultz, 1998).

Tonic orexin: Low-frequency baseline firing that maintains wakefulness. When chronically elevated by stress, sleep fragmentation, or untreated apnea, tonic orexin keeps the chemoreflex sensitized and the arousal system hyperreactive.

Phasic orexin: High-frequency bursts triggered by salient events or acute stress. Phasic orexin signals "this experience matters, encode this" and drives activity-dependent neuroplastic consolidation.

A DORA competitively antagonizes both OX1R and OX2R for 8-19 hours, blocking both tonic maintenance and phasic instruction. By flattening the phasic spikes, the DORA may limit the brain's ability to encode the new respiratory baseline that acetazolamide is creating. The system is effectively stabilized every night, which is clinically valuable, but the question is whether this stabilization also produces durable adaptation.

Direct Evidence: DORAs Fail at Consolidation

Post-training administration of suvorexant (a DORA) did not improve consolidation of new learned responses in mice.

The Stabilization-Adaptation Tradeoff

A recurring pattern in respiratory physiology: the same intervention can produce different effects depending on the timescale. What optimizes immediate stability may not optimize long-term adaptation, and what drives durable change may involve short-term discomfort.

The Revised Architecture: Shift, Buffer, Challenge

The revised protocol replaces the DORA with two agents that collectively achieve arousal management and sleep protection while preserving the orexin system for adaptive phasic signaling during controlled challenges.

Drug 1: Acetazolamide (The Baseline Shift)

Acetazolamide, administered daily at low dose in extended-release formulation (the treating clinician currently uses 125 mg; Verbraecken et al. used 250 mg in the durability study), is a carbonic anhydrase inhibitor that produces sustained brain extracellular fluid (ECF) acidosis. Bickler et al. (1988) demonstrated that brain ECF pH fell by 0.08 +/- 0.04 units and ECF bicarbonate fell by 1.7 +/- 1.3 mM after acetazolamide, even when compensatory hyperventilation lowered arterial PaCO₂. The drug produces sustained central acidosis that cannot be ventilated away.

This sustained acidosis drives neuroplastic adaptation in the RTN. Chronic acidotic exposure upregulates preprogalanin expression in Phox2b+ chemosensory neurons (Dereli et al., 2019). Galanin acts as an inhibitory brake on downstream respiratory pattern generators via GalR1 in the ventral respiratory column, reducing effective controller gain.

Galanin is also expressed in the glomus cells of the human carotid body (Di Giulio et al., 2014; Porzionato et al., 2010), with GalR1 and GalR2 present on those cells. Galanin co-localizes with nestin, a stem cell marker, in carotid body chemoreceptor cells (Mazzatenta et al., 2016), suggesting it serves as a neurogenesis signal for chemoreceptor cell differentiation.

Clinical durability evidence: Verbraecken et al. (1998) reported CAI reduction from 25 +/- 10 at baseline to 4 +/- 2 on drug, 5 +/- 3 one month off drug, and 3 +/- 1 six months off drug. This persistence far exceeds the drug's pharmacokinetic half-life and suggests structural neuroplastic adaptation.

Drug 2: Zuranolone (The High-Pass Filter)

Zuranolone (Zurzuvae), an FDA-approved oral neurosteroid, replaces the DORA as the arousal-management and sleep-protection agent. Originally approved for postpartum depression, zuranolone acts as a direct positive allosteric modulator of GABA-A receptors, providing the neurosteroid-type buffering that endogenous allopregnanolone provides in premenopausal women, without requiring enzymatic conversion from a precursor hormone.

The Neurosteroid GABA-A Mechanism

Zuranolone was engineered to mimic allopregnanolone (ALLO) with improved oral bioavailability and consistent dosing. In Phase 3 clinical trials, zuranolone demonstrated rapid and significant improvements in depressive and anxiety symptoms. Critically, it does not bind nuclear progesterone receptors (PR-A, PR-B), meaning it is not expected to suppress the hypothalamic-pituitary-gonadal axis. It can be administered to male patients without risk of testosterone suppression or endocrine disruption.

Clonazepam binds to the gamma-subunit of synaptic GABA-A receptors, amplifying rapid phasic inhibition. This suppresses the synaptic transmission required for respiratory adaptation and all forms of activity-dependent plasticity.

Zuranolone binds preferentially to extrasynaptic GABA-A receptors containing delta-subunits (e.g., alpha-4/beta-3/delta), with an EC50 of 118 nM at these receptors versus 430 nM at synaptic gamma-subunit receptors. This selectivity profile means at therapeutic concentrations, zuranolone preferentially provides tonic inhibitory buffering while leaving synaptic transmission relatively intact. It lowers the neural noise floor, raising the threshold for hyperexcitability and dampening background hyperarousal.

Because zuranolone acts extrasynaptically, it leaves the primary synaptic clefts fully operational. When a stressor triggers a burst of norepinephrine and orexin, the signal punches through the lowered noise floor to induce targeted neuroplastic change. Zuranolone may function as a high-pass filter: it suppresses tonic pathological arousal while preserving phasic adaptive signals. A DORA blocks orexin signaling broadly, including both tonic and phasic modes. Clonazepam attenuates synaptic transmission across multiple circuits.

A caveat: zuranolone is not without CNS effects. It carries a boxed warning for driving impairment due to somnolence and dizziness, and clinical trials showed dose-dependent sedation. While it preserves orexin availability far better than a DORA, elevated tonic inhibition will inevitably raise the threshold that the yohimbine challenge signal must overcome. The high-pass filter model is a hypothesis to be tested, not an established fact.

Physiological Precedent: Endogenous ALLO During Breath-Hold Training

Zuranolone replicates pharmacologically what the body produces naturally during intense respiratory training. During high-intensity breath holds and acute physical stress, the adrenal glands produce progesterone as a precursor to cortisol. A portion of this adrenal progesterone is converted to allopregnanolone in the brain. This means that during every breath-hold session, the practitioner is endogenously generating both the challenge signal (orexin, catecholamines) and the buffer (adrenal ALLO) simultaneously. The protocol reconstructs this natural pairing pharmacologically: yohimbine provides the challenge, zuranolone provides the buffer.

Respiratory Considerations

Zuranolone's role in the protocol is arousal management and sleep protection, not direct respiratory stimulation. It does not bind nuclear progesterone receptors and therefore does not directly affect medullary respiratory drive. Respiratory stabilization in this protocol relies on acetazolamide, which independently widens the CO₂ reserve and stabilizes breathing.

Addressing the Sex Difference

Women wean more easily than men. Multiple factors likely contribute to this difference, including sex differences in loop gain, airway anatomy, carotid body responsiveness, arousal threshold, and hormonal environment. Endogenous allopregnanolone is a candidate mechanism: premenopausal women produce allopregnanolone as a metabolite of progesterone, providing continuous neurosteroid-mediated GABA-A arousal buffering. Post-menopausal women lose much of this endogenous production, which may contribute to their increased vulnerability to sleep-disordered breathing after menopause. Men can generate transient ALLO through adrenal stress responses during intense physical exertion, but the magnitude is substantially lower than female luteal-phase concentrations, and the production is intermittent and effort-dependent. Zuranolone restores the neurosteroid buffer that aging and menopause deplete in both sexes. Men have higher peripheral chemosensitivity, higher hypoxic ventilatory response, and greater sleep-stage-related depression of hypoxic ventilatory response. Exogenous testosterone raises loop gain. Zuranolone provides a direct pharmacological equivalent of the endogenous ALLO buffer, and because it does not bind progesterone receptors, it can be administered to men without suppressing the hypothalamic-pituitary-gonadal axis.

Drug 3: Yohimbine (The Controlled Challenge)

Yohimbine, administered intermittently on specific challenge days during the treatment window at the dose utilized in the Powers et al. (2009) and Smits et al. (2014) trials (10.8 mg oral, approximately one hour before the challenge window), is a selective alpha-2 adrenergic receptor antagonist that increases central norepinephrine release and produces acute sympathetic activation. Its stress-challenge effects are mediated through OX1R, producing both noradrenergic and orexinergic activation simultaneously.

Published Efficacy as Stress-Challenge Agent

Published clinical trials demonstrate that yohimbine enhances the consolidation of new physiological and behavioral baselines across multiple paradigms. Powers et al. (2009) found an effect size of d = 1.68 for physiological adaptation during controlled stress exposure. Smits et al. (2014) confirmed a significant effect of d = 0.53 in a separate population. Tuerk et al. (2018) demonstrated potentiated autonomic reactivity changes consistent with deepened neuroplastic consolidation. The common mechanism across these studies is noradrenergic and orexinergic augmentation of activity-dependent encoding during controlled stress.

Dual-Target Chemosensory Challenge

Alpha-2 adrenergic receptors are present in the carotid body glomus cells. Yohimbine acutely heightens carotid body chemoreceptor sensitivity, potentiating the response to hypoxia by up to 46%. In the NTS, yohimbine alters action-potential-evoked responses, forcing reorganization of how the brainstem interprets chemosensory input.

Intermittent yohimbine challenges the carotid body and RTN through two pathways: peripheral chemoreceptor activation via alpha-2 blockade in the glomus cells, and central noradrenergic/orexinergic activation that drives the consolidation cascade. Each session is a pharmacological simulation of the struggle phase of a maximal breath hold, without the hypoxemia, hypercapnia, and arrhythmia risk of actual apnea.

Pairing with EERS: The Hebbian Requirement

For the yohimbine-driven orexin spike to consolidate respiratory adaptation specifically, the chemosensory synapses must be actively firing during the consolidation window. Yohimbine alone, administered in a state of quiet normoxic breathing, provides the consolidation signal but may not adequately activate the target circuits. The solution is to pair the yohimbine challenge with an awake, supervised daytime EERS session (Enhanced Expiratory Rebreathing Space), which provides controlled CO₂ rebreathing that directly activates carotid body and RTN chemosensory neurons. EERS is already a standard component of the clinical weaning protocol. During the yohimbine challenge window, EERS provides the specific chemosensory activation that tells the respiratory synapses to fire, while yohimbine provides the orexin-mediated signal that tells the system to consolidate that firing pattern into durable hardware.

Timing: The Chronopharmacology of the Challenge

The yohimbine challenge should be conducted in the morning or early afternoon. This allows the sympathetic rebound to clear fully before the sleep period, preventing the orexin spike from fragmenting nighttime sleep architecture and overriding zuranolone's protective buffering. Acetazolamide's continuous 24-hour presence bridges the gap between daytime challenge and nighttime consolidation: the pH baseline shift is always active, meaning the chemosensory environment the system is adapting to does not change between waking and sleeping states.

Safety: Yohimbine vs. Maximal Breath Hold

Why Yohimbine Was Previously Contraindicated

In the original protocol that included a DORA, yohimbine was contraindicated. Its stress-challenge effects are mediated through OX1R, which the DORA blocks. With the DORA removed and replaced by zuranolone, yohimbine's OX1R-dependent mechanism is fully available. The orexinergic activation provides the consolidation signal that breath holds naturally produce during chemoreflex training.

Patient Selection and Exclusions

The intermittent challenge component requires careful patient selection. Yohimbine produces acute sympathetic activation, and in certain populations this becomes pathological rather than adaptive. Exclusions should include heart failure, atrial fibrillation, uncontrolled hypertension, significant arrhythmia history, and seizure risk. These are not generic safety precautions; they are mechanistically central. Heart failure and AF patients cannot wean because their instability comes from circulatory delay, not controller gain. Adding a sympathetic challenge to a system whose instability is structural rather than neuroplastic is counterproductive. For included patients, blood pressure and electrolyte monitoring should accompany each challenge session, given that acetazolamide alters electrolyte balance and yohimbine acutely elevates sympathetic tone.

Reconciling the Clinical Observations

The 20/80 Weaning Split

The 20% who successfully wean may be patients whose systems generated enough galanin-mediated adaptation despite the DORA's suppression of orexin-mediated consolidation. If a protocol preserving orexin availability were tested alongside intermittent challenge sessions, the weaning success rate might differ. A testable retrospective question: did the clinician observe different weaning success rates during his earlier clonazepam era versus his current DORA era?

Men Are Harder

Men lack endogenous progesterone and allopregnanolone. Without ALLO, men have no endogenous extrasynaptic GABA-A arousal buffer and no neurosteroid-mediated respiratory stabilization. Their carotid bodies are more reactive, their loop gain runs higher, and the system resists recalibration. Zuranolone provides this neurosteroid buffering without endocrine disruption.

Heart Failure and Atrial Fibrillation

In heart failure, respiratory instability is driven by massive circulatory delay due to reduced cardiac output. The chemoreceptors act on stale blood gas information. This is a structural cardiac deficit, not a chemoreceptor sensitivity problem. No amount of chemoreceptor recalibration can overcome a fixed circulatory delay. Atrial fibrillation adds stochastic beat-to-beat variability that further destabilizes the feedback loop.

Sedatives Needed Long-Term

Acetazolamide shifts the chemoreflex side through a pH-mediated transcriptional adaptation (galanin) that persists after the drug is removed. Sedatives address arousal threshold through a different pathway that does not self-recalibrate through the same RTN mechanism. Zuranolone provides GABA-A arousal management through a neurosteroid mechanism rather than a benzodiazepine. Whether neurosteroid-mediated tonic inhibition can eventually be tapered is an empirical question.

The Carotid Body as Plasticity Nexus

The carotid body was identified by the clinician as "maybe the most plastic neural structure." It contains quiescent multipotent stem cells that differentiate under sustained stress. Galanin expression in the chemoreceptor cells has been proposed as the neurogenesis signal (Mazzatenta et al., 2014, 2016). The same neuropeptide that acetazolamide drives in the RTN is also the plasticity signal in the carotid body. Carotid body plasticity can be adaptive or maladaptive depending on stimulus pattern; the protocol aims to bias that plasticity toward reduced pathological gain rather than sensitization.

Subclinical Chemosensory Triggers

The clinician described patients with minimal apnea but excessive cyclic alternating pattern and "horrible responsivity." These arousals may not be spontaneous. Subclinical CO₂/pH fluctuations could activate the chemosensory relay and trigger cortical arousals. As the clinician noted: "I suppose volcanic eruptions can also be 'spontaneous.'"

Years vs. Rapid Improvement

Patients with recent-onset sensitization have not yet hardened the synaptic architecture of the chemoreflex. Their systems reset quickly because the pathological plasticity is still labile. Chronic patients require proportionally longer treatment.

EERS: Controller vs. Plant Gain

Acetazolamide targets controller gain via galanin-mediated neuroplasticity. EERS targets plant gain via mechanical CO₂ rebreathing. The 20% who wean off acetazolamide while remaining on EERS may be patients whose controller gain was durably reduced, leaving only plant gain instability to manage mechanically.

The Clonazepam-to-DORA Transition

The transition from acetazolamide + clonazepam to acetazolamide + DORA improved nightly sleep quality and reduced dependency risk. The question is whether a protocol optimized for nightly treatment may reduce the opportunity for the kind of durable neuroplastic recalibration that would eventually make the treatment unnecessary. Clonazepam leaves the orexin system intact. The DORA blocks it. Zuranolone represents a third option: GABA-A modulation through a neurosteroid mechanism that preserves orexin and avoids benzodiazepine dependency.

Protocol Coherence

No drug conflicts with any other. Acetazolamide shifts the pH environment. Zuranolone buffers arousal without touching orexin. Yohimbine provides the intermittent challenge with full orexin availability.

The Organizing Principle

Durable recalibration requires baseline shifting plus intermittent challenge. Chronic suppression alone stabilizes without teaching. The system may not learn a new operating state from comfort. It learns from controlled challenge followed by recovery. The controlled discomfort may be the adaptive stimulus. The orexin spike may be the consolidation signal. Suppressing it may be suppressing the adaptation.

Proposed Validation Metrics

Future trials testing this framework should not rely solely on weaning success or AHI reduction. Structural neuroplastic adaptation requires objective measurement. Two approaches are recommended: CPAP dial-down studies, in which CPAP pressure is systematically reduced during sleep to mathematically isolate and quantify changes in controller gain independent of plant gain; and daytime hypercapnic ventilatory response (HCVR) testing, conducted at baseline and at intervals throughout the protocol, to track whether the chemosensitivity curve is structurally flattening over time. A measurable reduction in HCVR slope would constitute direct evidence that the protocol is producing durable ventilatory long-term depression rather than transient pharmacological stabilization. Additionally, formal retrospective chart review comparing weaning outcomes in DORA-treated versus non-DORA-treated cohorts (including historical clonazepam-era patients) would provide the first direct clinical evidence for whether orexin blockade specifically correlates with weaning difficulty.

References

Original bibliography wording is preserved. Linked source records identify verified bibliographic corrections; searches are labeled as searches.

1. Aston-Jones G, Cohen JD (2005). An integrative theory of locus coeruleus-norepinephrine function. Annu Rev Neurosci, 28:403-450.
   Read sourceAbstractSource record & notes
2. Bickler PE, Litt L, Banville DL, Severinghaus JW (1988). Effects of acetazolamide on cerebral acid-base balance. J Appl Physiol, 65(1):422-427.
   Read sourceAbstractSource record & notes
3. Dereli AS, Yaseen Z, Carrive P, Kumar NN (2019). Adaptation of respiratory-related brain regions to long-term hypercapnia. Front Neurosci, 13:1343.
   Read sourceAbstractOpen full textSource record & notes
4. Di Giulio C et al. (2014). Selective expression of galanin in neuronal-like cells of the human carotid body. Adv Exp Med Biol, 860:315-323.
   Read sourceAbstractSource record & notes
5. Kumar NN et al. (2025). Human RTN Phox2b neuron characterization. bioRxiv preprint.
   Read sourceAbstractOpen full textSource record & notes
   Bibliographic note: The cited preprint shorthand resolves to a peer-reviewed 2025 article with Liu as first author. The published anatomical characterization identifies putative human RTN neurons; it is not a functional intervention study.
6. Li A, Nattie E (2010). Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness. J Physiol, 588(Pt 15):2935-2944.
   Read sourceAbstractOpen full textSource record & notes
7. Mazzatenta A et al. (2014). In the carotid body, galanin is a signal for neurogenesis. Front Physiol, 5:427.
   Read sourceAbstractOpen full textSource record & notes
8. Mazzatenta A et al. (2016). Coexpression of galanin and nestin in the chemoreceptor cells of the human carotid body. Adv Exp Med Biol, 885:77-82.
   Read sourceAbstractSource record & notes
9. Messineo L et al. (2018). Breath-hold duration as a measure of respiratory loop gain. J Physiol, 596(22):5343-5352.
   Read sourceAbstractOpen full textSource record & notes
   Bibliographic note: Pharmacological recalibration reference gives a different title and incorrect volume/pages; verified article is 596(17):4043–4056. Maximal breath-hold testing was evaluated as a marker of loop gain, not as a therapeutic training intervention.
10. Ni YN, Yang H, Thomas RJ (2021). Role of acetazolamide in sleep apnea at sea level. J Clin Sleep Med, 17(6):1295-1304.
    Read sourceAbstractOpen full textSource record & notes
    Bibliographic note: Verified second author is Yang H, not Yang Y in the throughput bibliography.
11. Porzionato A et al. (2010). Expression and distribution of galanin receptor subtypes in the rat carotid body. Mol Med Rep, 3:37-41.
    Read sourceAbstractSource record & notes
12. Powers MB, Smits JAJ, Otto MW, Sanders C, Emmelkamp PMG (2009). Facilitation of fear extinction in phobic participants with a novel cognitive enhancer. J Anxiety Disord, 23(6):741-745.
    Read sourceAbstractSource record & notes
    Bibliographic note: Verified article is J Anxiety Disord 23(3):350–356; supplied 23(6):741–745 pages are incorrect.
13. Smits JAJ et al. (2014). Yohimbine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry, 75(11):840-846.
    Read sourceAbstractSource record & notes
14. Tuerk PW et al. (2018). Yohimbine augmentation of exposure therapy for combat-related PTSD. Behav Res Ther.
    Read sourceAbstractSource record & notes
    Bibliographic note: Verified article appeared in Cognitive Behaviour Therapy 47(5):351–371; the supplied Behavior Research and Therapy journal is incorrect.
15. Verbraecken J et al. (1998). Central sleep apnea after interrupting long-term acetazolamide therapy. Respir Physiol, 112(1):59-70.
    Read sourceAbstractSource record & notes